MCP-1 plays critical role in mediating photoreceptor apoptosis

Article

Monocyte chemoattractant protein 1 (MCP-1) seems to be responsible for apoptosis of the photoreceptors in certain visual disorders.

Key Points

Joan W. Miller, MD, and colleagues demonstrated that MCP-1 has a critical role in mediating photoreceptor apoptosis after retinal detachment in an experimental murine model. Specifically, MCP-1 causes macrophages and microglia to accumulate and generate oxidative stress in the retina. She reported the findings of her group at the Retina Society meeting in Boston.

She is chairwoman, Department of Ophthalmology, Harvard Medical School, and chief of ophthalmology and Henry Willard Williams Professor of Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston. The investigators reported their findings in the Proceedings of the National Academy of Sciences (2007;104:2425-2430).

"Because of this, new insights about the mechanisms that underlie photoreceptors' apoptosis in retinal detachment would be of clinical interest and could lead to new treatments," she said.

Suppression of caspases alone, which Dr. Miller and colleagues indicate is associated with death of photoreceptors as the result of retinal detachment, cannot stop apoptosis.

Dr. Miller explained that MCP-1 causes leukocytes to accumulate in diseases involving atherosclerosis, pulmonary infections, or angiogenesis, as well as some central nervous system disorders. In addition, MCP-1 is present in very high levels in vitreous samples from patients with retinal detachment compared with samples from patients with macular hole or idiopathic premacular fibrosis.

In the study under discussion, the authors used a murine model in which retinal detachments were induced in the right eyes of the mice. The animals received a subretinal injection of MCP-1 blocking antibody.

The authors found that the level of MCP-1 mRNA levels in the retina had increased 84-fold by 72 hours after the creation of the retinal detachments, and protein levels increased 10-fold compared with the baseline value.

"MCP-1 immunoreactivity was very weak in the normal controls, but spindle-shaped cells, which morphologically resembled Muller glia, were strongly MCP-1-immunoreactive in the outer plexiform layer after retinal detachment," they reported.

The results also showed that mice that are deficient in MCP-1 had significantly reduced infiltration of macrophages and microglia following the creation of retinal detachment and little photoreceptor apoptosis.

When the authors cultured primary adult retinal cultures to study whether increased MCP-1 is involved in photoreceptor death, MCP-1 was found not to affect the survival of the photoreceptors when the macrophages and microglia were removed from the cell cultures. They reported, however, that "without depletion of CD11b+ cells from the retinal cultures, the number of recoverin+ photoreceptors declined progressively with increasing MCP-1 concentrations, and MCP-1 concentrations as low as 0.1 mg/ml had significant cytotoxic effects. These data suggest that MCP-1's cytotoxicity is mediated through resident macrophage/microglia but not through direct interaction with the cultured photoreceptors."

In this experimental murine model of retinal detachment, Dr. Miller said, MCP-1 may be an important mediator of the macrophage and microglial responses in some retinal diseases. She pointed out that in a previous study of a retinal ischemia-reperfusion model conducted by Nakazawa and colleagues (Curr Eye Res 2003;26:55-63), MCP-1 was up-regulated in the inner retina only.

"In the current study, MCP-1 protein expression was detected in Muller cells, especially in the outer plexiform layer," Dr. Miller said. "The outer plexiform layer has a rich vascular capillary bed, which would facilitate extravasation of leukocytes."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
© 2025 MJH Life Sciences

All rights reserved.